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Classical gene targeting has identified many genes important
for fetal and placental development. Null mutation of these
genes may lead to fetal growth restriction, malformation or
embryonic death. Growth restriction of epigenetic basis can
predispose to adult-onset diseases. The mechanisms
underlying this process, termed ‘fetal programming’, are
beginning to be understood.
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Abbreviations
E embryonic day
HERV human endogenous retrovirus
HIF hypoxia-inducible factor
IGF insulin-like growth factor
IGFBP IGF binding protein
TGF transforming growth factor
uNK cells uterine natural killer cells
VEGF vascular endothelial growth factor
VEGFR VEGF receptor
Introduction
Fetal development entails a series of complex events,
including differentiation into embryonic and extraembryonic
cell lineages and interaction with maternal tissues through
a yolk sac and chorioallantoic placenta. Vasculogenesis and
angiogenesis to establish a fetal circulation are among the
critical early events. Much current research is focused on
understanding the genetic control of these complex 
interactions. With the advent of transgenic and gene-
targeting methodologies to determine the biological roles
of genes during development, the mouse has become
an increasingly important experimental model. Traditional
gene-targeting approaches lead to an annulment of gene
expression in early gestation and affect the development of
both the fetus and placenta. Many of the genes shown in
this manner to be essential for fetal survival affect
development of the yolk sac and placenta or the vascular
system of the conceptus. 
Death of the null mutants may be sudden, as in the case of
Mash2 or Vcam1 mutations, in which the chorioallantoic
placenta fails to form. In other cases, death is preceded by
growth retardation. It is important to recognize that these
effects on growth are often secondary to a restricted supply
of nutrients. However, a few genes have been shown to
control cell replication and overall growth directly.
Efstratiadis [1] identified 20 growth control genes in mice
and only half of these affected birth weight. Seven of the
genes are known to control fetal growth code for insulin,
insulin-like growth factors I and II (IGF-I, IGF-II), their
receptors and the receptor substrates. There have been no
additions to this list over the past year and this review
describes our current understanding of how these genes
affect the development of placental and fetal systems. 
The sequelae of poor fetal growth extend well past the
postnatal period. Low birth weight has been linked to
adult-onset diseases that include hypertension and non-
insulin dependent diabetes mellitus [2]. A second focus of
this review will be to explore the endocrine responses of
the fetus that may lead to an alteration of fetal growth.
This process is referred to as ‘programming’, a term that
encompasses genetic and epigenetic events associated with
low birth weight. 
Placental development
Placental structure varies greatly across species and 
comprises a bewildering array of cell types. One of the 
earliest events in embryonic differentiation is the formation
of trophectoderm, which gives rise to all the subsequent
trophoblast lineages. These include various forms of
cytotrophoblast, in which the cells remain discrete, and
syncytiotrophoblast, in which cell fusion has occurred. Cells
that invade the maternal tissues in man and primates are
called extravillous trophoblasts. Vascularization of the pla-
centa from the fetal side requires fusion of the trophoblastic
chorion with the allantois and subsequent penetration of
the trophoblast by fetal mesenchyme-bearing capillaries.
In the definitive chorioallantoic placenta of the mouse,
there are three principal cell layers: the labyrinth, or
exchange area; the spongiotrophoblast layer; and the giant
cells. The spongiotrophoblasts arise early in development
and are thought to give rise to the other cell types (see also
Update). The giant cells at the periphery of the placenta
have undergone terminal differentiation and are polyploidal.
Gene knockout experiments in mice continue to shed light
on the factors involved in placental development (Table 1).
One of the earliest events, separation of the embryonic and
extraembryonic cell lineages, requires the T-box gene
Eomesodermin. In Eomes–/– embryos, the trophectoderm
fails to differentiate into trophoblast [3•]. Cytokeratins
play a key role in the further differentiation of the 
trophoblast. In mice lacking both cytokeratin 8 and 19, the
placenta lacks spongiotrophoblast and labyrinthine 
trophoblast [4]. Establishment of the placental labyrinth
requires extensive folding of a sheet of trophoblast cells.
This occurs in response to contact with the allantois and
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requires the transcription factor GCM1 (glial cells
missing 1). The labyrinth fails to develop in Gcm1–/– mice,
resulting in death by embryonic day 10 (E10) [5•]. The 
signaling pathways involved in placental development
involve p38α mitogen-activated protein (MAP) kinase. In
p38α–/– mice, there is significant reduction of spongio-
trophoblast and almost complete loss of the labyrinth 
layer [6•]. These mutants are conspicuous examples of 
embryonic lethality resulting from disruption of placental
components essential for survival.
A key role in trophoblast differentiation has been ascribed
to genes of retroviral origin. Such genes comprise about 1%
of the human genome and, serendipitously, transcription of
Table 1
Some genes recently found to be essential for normal growth and development of the yolk sac, placenta and embryo in mice.
Gene Gene product Phenotype of yolk sac and placenta* Phenotype of embryo* Refs
Eomes Eomesodermin, a T-box gene Trophectoderm fails to develop into trophoblast Death at blastocyst stage [3•]
product
Talin Cytoskeletal protein Ectoplacental and exocoelomic cavities fail to form Failure of cell migration at gastrulation. [54]
Death at E8.5–9.5
Fzd5 Frizzled protein, a receptor for Defective yolk sac angiogenesis and placental Normal vasculogenesis in embryo. [55]
Wnt signaling molecules vasculogenesis Death at E10.75
Krt2–8, Cytokeratins 8, 18 and 19 Double knockout of 8 and 19: giant cells fail to Death at E9.5 [4,56]
Krt1–18, differentiate into spongiotrophoblast and 
Krt1–19 labyrinthine trophoblast
Double knockout of 18 and 19: giant-cell
necrosis
Foxf1 A forkhead transcription factor No vasculogenesis in yolk sac or allantois. Reduced mesodermal proliferation in [57]
Chorioallantoic fusion fails and amnion does not primitive streak and somite formation
expand retarded. Death at E10
Epas1 HIF-2α, a basic helix-loop-helix Vascular defects in yolk sac due to failure of Vascular defects due to failure of [13•]
PAS transcription factor vascular remodeling following vasculogenesis vascular remodeling. Fetal death at 
E9.5–12.5
Tgfbr1 TGFβ type 1 receptor Impaired yolk-sac vascularization (cause of death) Neural tube defects. Death at around E10.5 [58]
and inhibition of placental angiogenesis
Gcm1 Glial cells missing 1, a Allantois fuses with chorion but labyrinth fails to Death at E9.5–10 [5•,59]
transcription factor develop
P38α P38α MAP kinase, a signaling Reduced spongiotrophoblast, loss of labyrinth, Defective angiogenesis. Reduction of [6•,60]
molecule defective yolk-sac angiogenesis myocardium. Death at E10.5–12.5
Map3k3 MEKK3, a signal transduction Disruption of placental angiogenesis and of Death at E11 [61]
molecule in the p38α MAP structural integrity of yolk sac
kinase cascade
cRaf-1 Raf kinase, a component of the Reduction of labyrinth and spongiotrophoblast. Liver small, hypocellular and with numerous [62]
ERK cascade Poor vascularization apoptotic cells. Anaemia. Death at 
E11.5–13.5
Fra1 AP-1 transcription factor Placental labyrinth largely avascular. Defects in  Severe growth retardation. Death at [63]
yolk sac E10–10.5.
Arnt Nuclear translocator that Abnormal development of labyrinth with decreased Embryonic blood vessels develop normally. [12•]
dimerizes with HIF-1α VEGFR2 and VEGF binding Death at E10.5.
Gab1 Docking protein, binds cMet Placental labyrinth severely reduced Impaired migration of myogenic cells. [64]
receptor kinase Reduced liver size. Death at E13.5–18.5
Abca1 ATP-binding cassette Disrupted placental architecture in Abca1 (–/–) Severe growth retardation. Death at E14 [65,66]
transporter  due to lack of HDL-C and altered 
ApoA1 Apolipoprotein A1 Not described for ApoA1 (–/–) steroidogenesis
Has2 Hyaluron synthase 2 Yolk sac endoderm and mesoderm fail to fuse and Severe cardiac and vascular abnormalities [14]
blood vessels are lacking and growth restriction. Death at E9.5–10
Gdf1 Growth/differentiation factor 1 Not described Defects related to left–right patterning, [16•]
(TGFβ family) including visceral situs inversus and
cardiac anomalies. Death at E14.5 or later
Smad5 Component of TGFβ family Not described Defects related to left–right patterning. [15]
signaling cascade Death at E9.5–11.5
Adm Adrenomedullin, first described Not described Cardiovascular abnormalities and extreme [17]
as a vasodilator hydrops fetalis. Death at E13.5–14.5
*Phenotype of null mutants (–/–). cMET, hepatocyte growth factor receptor; ERK, extracellular-signal-regulated protein kinase; HDL-C, high-density
lipoprotein cholesterol; MAP kinase, mitogen-activated protein kinase; MEKK3, MAP/ERK kinase kinase 3.
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the envelope region of human endogenous retrovirus 3
(HERV-3) was found to occur during normal trophoblast
differentiation. BeWo cells stably transfected with the
HERV-3 env gene undergo differentiation that includes
inhibition of cell proliferation, through modulation of the
cell-cycle regulators cyclin B and p21, and secrete 
chorionic gonadotrophin [7]. Another member of the
HERV family (HERV-W), with the functional properties of
a retrovirus envelope, is expressed specifically in the 
placenta and encodes a protein termed syncytin [8••,9].
The expression of recombinant syncytin in a variety of cell
types induces the formation of giant syncytia and an anti-
syncytin antiserum inhibits fusion of a human trophoblast
cell line [8••]. These results indicate that this protein is
important in the differentiation of cytotrophoblasts into
syncytiotrophoblast. Why a retroviral genome became
incorporated into a human genome and encodes a protein
that is essential for fetal survival will be the subject of
intense research interest in the next few years.
Differentiation of trophoblast towards a more invasive
phenotype early in pregnancy is thought to be stimulated
by the comparatively low oxygen tension in the uterus.
Exposure of first trimester human villous explants to
low oxygen tension triggers trophoblast proliferation,
fibronectin synthesis, α5 integrin expression and gelati-
nase-A activity [10•]. These effects are, in part, mediated
by transforming growth factor β3 (TGFβ3). They are inhib-
ited following antisense expression of hypoxia-inducible
factor 1α (HIF-1α), which instead triggers expression of
markers of an invasive phenotype, such as α1 integrin and
gelatinase-B. Thus, the oxygen-dependent events of early
trophoblast differentiation are, in part, mediated by
TGFβ3 through HIF-1 transcription factors [10•].
Cardiovascular development
Factors important in vasculogenesis and angiogenesis
include vascular endothelial growth factor (VEGF), the
related placental growth factor, their receptors (VEGFR-1
and VEGFR-2), angiopoietin and the angiopoietin receptors
(Tie-1 and Tie-2) [11]. Null mutation of the aryl hydrocar-
bon nuclear translocator (ARNT), a transcriptional regulator
that dimerizes with HIF-1α, indicates that angiogenesis is
differentially regulated in placenta, yolk sac and embryo
[12•]. In Arnt–/– mice, abnormal development of the placental
labyrinth was found to be associated with reduced VEGF
binding and decreased expression of VEGFR-2. In contrast,
vascular development was normal in the yolk sac and
embryo, and seemed here to be dependent on VEGFR-1.
HIF-2α was also required for normal vascular development
and appeared to be important for the vascular remodeling
that follows vasculogenesis and angiogenesis [13•].
Hyaluronic acid has been assigned a role in cell migration
and tissue remodeling. Mice null-mutant for hyaluronan
synthase 2 had severe cardiovascular anomalies. The yolk
sac endoderm and mesoderm failed to fuse and vitelline
vessels were lacking [14]. 
Components of the TGFβ family and its signaling system
are essential for left–right patterning. Their absence leads
to cardiovascular anomalies that result in embryonic death
[15]. Left–right patterning of abdominal organs is separately
controlled. Abnormal displacement of the viscera to the
opposite side of the body (situs inversus) occurs in the
absence of growth/differentiation factor 1 [16•]. Although
Gdf1–/– mutants can show aberrant left–right patterning of
the heart and lungs, this is independent of whether or not
positioning of the abdominal organs is affected [16•].
Finally, adrenomedullin — encoded by Adm and best
known as a potent vasodilator — may play a role in cardio-
vascular development. Adm–/– mutants die at midgestation
with extreme hydrops fetalis and cardiovascular abnormal-
ities that include hypertrophied ventricular trabeculae and
underdeveloped arterial walls [17]. Although there was a
marked increase in amniotic fluid volume, Adm expression
in fetal membranes was not examined. However,
adrenomedullin has been demonstrated in human amniotic
epithelium by immunohistochemistry [18].
Maternal placental vasculature
In human and primate placentae, the maternal blood 
supply is from the spiral arteries of the uterine wall. These
open directly into the intervillous space, where maternal
blood comes in direct contact with the syncytiotrophoblast
of the fetal villi (hemochorial placentation). Remodeling
and widening of the spiral arteries is essential to ensure an
adequate maternal blood supply to the uterus and includes
replacement of the vessel endothelium with extravillous
trophoblast. Tie-2 receptor is expressed in these 
endovascular trophoblasts and in maternal endothelium,
suggesting a role for angiopoietin-2 in remodeling of the
maternal vessels [19].
Vascular remodeling of uterine arteries without trophoblast
invasion is an interesting feature of mouse pregnancy. It is
known to be dependent on uterine natural killer cells (uNK
cells), as pregnancy-induced changes in the arteries are not
initiated in mice that fail to develop uNK cells and this effect
can be reversed by uNK cell grafts [20]. Arterial remodeling
is dependent on interferon-γ (IFNγ) secretion from uNK
cells and occurs normally following administration of recom-
binant IFNγ to mice that lack uNK cells [21]. Concurrent
with uterine vascular development, VEGF mRNA and pro-
tein increase in the decidua and the metrial gland, where the
uNK cells reside, and it was shown by immunohistochemistry
that VEGF was located to uNK cells [22]. 
As many as 10% of all genes are subject to parental
imprinting, the monoallelic expression of genes depending
on parental legacy. Several of these imprinted genes are
critical to placental development. In the case of the Igf2
gene, the phenotype of the offspring is determined by the
paternal allele. In contrast, the phenotype of the IGF
clearance receptor, Igf2r, is determined by the maternal
allele [1]. Recently it was found that there is another set of
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imprinted genes, on mouse chromosome 12, that is 
needed for normal trophoblast development, vascularization
and invasion. Interestingly, these genes impact on
fetal–maternal interactions. Thus, transformation of the
wall of the maternal artery was not complete in pregnancies
where a conceptus had been generated with paternal
uniparental disomy for chromosome 12 [23••].
Inadequate remodeling of the spiral arteries, due to failure
of a second wave of trophoblast invasion, has been linked to
preeclampsia. This disease is characterized by widespread
endothelial dysfunction and is caused by a circulating factor
or factors of placental origin. Incubation of myometrial
arteries from normotensive pregnant women with plasma
from women with preeclampsia caused a large reduction in
endothelium-dependent regulation [24]. A similar effect
was seen when the vessels were incubated with VEGF, but
neither VEGF nor preeclamptic plasma affected vascular
reactivity in the presence of an antibody to the VEGFR-1.
This suggests that placentally derived VEGF and its receptor
play a central role in the pathogenesis of preeclampsia [25].
Important factors in fetal growth
Insulin-like growth factors 
IGF-I and IGF-II are mitogenic peptides that also promote
differentiation, migration and aggregation and inhibit apoptosis.
Their biological roles in fetal and placental development have
been further delineated by in vivo and in vitro studies. As
shown recently for the mouse [26] and non-human primate
[27], these peptides are synthesized at specific times and 
locations during development to exert their regulatory 
function in an autocrine and/or paracrine manner. 
Birth weight in humans has been correlated positively to IGF-I
levels in umbilical cord blood [28]. Placental weight was shown
recently to correlate with the ratio between IGF-II in cord
blood and a soluble, circulating form of the IGF type 2 receptor
(IGF2R) that inhibits IGF-II-mediated DNA synthesis [29].
Placental weight also correlated with levels of IGF-I and of
IGF binding protein (IGFBP)-3 in cord blood [29].
IGF-II has recently been implicated in the fetal overgrowth
that occurs in cattle following in vitro fertilization and
embryo transfer. IGF-II mRNA levels were twofold greater
in these fetuses than in controls when measured at day 70
of gestation [30].
The biological effects of IGFs are mediated by the type 1
IGF receptor (IGF-1R), the IGF-II/mannose-6-phosphate
receptor and the insulin receptor. Igf1r–/– newborn mice are
severely growth-restricted and die postnatally because of
respiratory problems [31]. However, when the Igf1r gene
was targeted using a construct that reduced IGF-binding
sites by 41% in the homozygotes, prenatal and immediate
postnatal growth was normal [32].
The bioavailability and biological actions of IGFs are
regulated by a family of six high-affinity IGF binding
proteins (IGFBP-1 to -6) [33]. The Igfbp genes are
considered not to be growth control genes [1]. Accordingly,
Igfbp2–/– mice have normal birth weights [34] and even mice
with combinatorial knockouts of IGFBPs fail to show a fetal
phenotype [35]. However, the fetus responds to hypoxia,
nutrient deprivation and stress by upregulating IGFBPs,
thereby restricting fetal growth [36,37]. Subjecting Igfbp–/–
mice to growth-restrictive conditions may result in different
outcomes compared with wild-type mice. These may be
useful models to study the role of IGFBPs in fetal growth.
Leptin 
Leptin is a hormone secreted by adipose tissue that
regulates food intake and energy balance. The placenta is
one of the major sources of leptin in the fetal circulation
[38]. There is no clear evidence that leptin affects fetal
growth but growth-restricted human fetuses do have
reduced leptin expression in the placenta and lower leptin
levels in cord blood [39]. A role for leptin in mouse devel-
opment is suggested by the recent demonstration of leptin
receptors in various fetal tissues of the mouse [40].
Fetal programming
Poor nutrition or lack of oxygen during fetal development
will impact on fetal growth rate, resulting in lower birth
weight and increased perinatal morbidity. In addition, it is
recognized that developmental alterations associated with
growth restriction may have long-term consequences.
Thus, low weight at birth has been linked to an increased
risk for adult-onset diseases, including hypertension,
ischemic heart disease and non-insulin-dependent diabetes
mellitus [2]. Because of its implications for adult health
and disease, ‘fetal programming’ is the focus of much
current research in fetal physiology. Glucocorticoids have
been ascribed a pivotal role in fetal programming. Thus,
exposure of fetal sheep to dexamethasone for 2 days at day
27 of gestation (term is ~150 days) was sufficient to trigger
hypertension that persisted until the adults were at least 5
years of age. These animals did not develop insulin resis-
tance, suggesting different timing for the programming of
fetal blood pressure and in sensitivity to insulin [41•].
Dietary restriction in rats also caused fetal growth restric-
tion. The offspring had high blood pressure and increased
plasma levels of insulin and leptin. In addition, they were
hyperphagic and become obese. These effects were
ascribed to impaired neuroendocrine regulation as a result
of fetal undernutrition [42]. 
To fully understand the link between low birth weight and
adult-onset diseases, account must be taken of the factors
that control fetal growth and those that impact on organ
systems critical to blood pressure control and glucose
homeostasis. Glucocorticoids have been assigned a central
role in fetal programming, but there must necessarily be
interaction with the IGF system (Figure 1).
The kidney may play an important role in prenatal 
programming of hypertension. The number of glomeruli in
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the kidney was found to be reduced by 28–29% in rats that
had low birth weight due to dietary restriction, but had
achieved full catch-up growth during the first weeks of life
[43•]. A progressive deterioration in renal function was seen in
hypertensive rats subjected to growth restriction in fetal life,
suggesting that hemodynamic adaptations to maintain renal
function following the reduced nephrogenesis caused a more
rapid progression to renal failure [44]. Rodent experiments
have further suggested involvement of the renin–angiotensin
system in fetal programming for hypertension, possibly acting
downstream of glucocorticoids. In support of this, the hyper-
tension that develops in rats following dietary restriction in
pregnancy can be prevented by treatment with losartan, an
angiotensin AT1 receptor antagonist, between 2 and 4 weeks
postnatally. The implication of this experiment is that fetal
influences may alter postnatal vascular responsiveness [45]. 
Moderate maternal exercise started early in pregnancy,
during the phase of rapid placental growth, may be a
strategy to improve fetal well-being. In a recent controlled
study, the offspring of exercising women were found to be
significantly heavier and longer at birth [46•]. It remains to
be determined whether a similar exercise regimen would
prove beneficial in women who are at sociodemographic
risk of having a low birth weight infant.
Conclusions and future directions
DNA microarray technology
Our understanding of how fetal and placental growth is
controlled is likely to be enhanced by DNA microarray
technology. There is now a cDNA microarray that contains
more than 15 000 genes expressed during development 
in mice. An initial application to the midgestation (E12.5) 
conceptus identified 289 genes that were more highly
expressed in the placenta than in the embryo, only 30 of
which had previously been reported [47••]. Potential appli-
cations of microarray technology include detecting genes
that change expression during embryonic or extraembryonic
development and identifying downstream target genes in
transgenic and knockout mice [47••].
Tissue-specific gene targeting
Tissue-specific gene activation and inactivation is now
possible using the Cre-recombinase-loxP (Cre-loxP) system.
Cre recombinase is an enzyme of bacteriophage origin
that catalyses recombination between two of its recognition
sites, loxP. Insertion of loxP sites into a gene can
usually — although not inevitably — be achieved without
affecting gene expression. Excision of the region flanked by
the loxP sites will occur only upon expression of Cre
recombinase, which can be driven by a tissue-specific
promoter. This will activate or, more usually, inactivate the
gene (conditional knockout) [48]. The simplest strategy to
achieve this is to cross a loxP provider mouse line and a
Cre-expressing transgenic line (Figure 2).
Application of this methodology to fetal and placental devel-
opment has hitherto been limited, because Cre transgenic
mice that have been developed so far use promoters that are
activated postnatally or only late in fetal development. A 
Figure 1
Fetal programming is thought to explain the
correlation between low birth weight and adult
hypertension. The IGF system and the
hypothalamic–pituitary–adrenal (HPA) axis are
likely to be equally important in this context.
Growth control genes include those coding
for insulin, IGF-I and IGF-II. Fetal responses to
hypoxia include downregulation of these
genes and increased expression of inhibitory
IGFBPs. Hypoxia also activates the HPA axis,
raising plasma levels of adrenocorticotropic
hormone (ACTH) and cortisol. This is a further
mechanism for regulating IGFBP expression.
Kidney growth is affected by reduced IGF
action, and possibly by increased cortisol
levels, resulting in a reduced number of
glomeruli. There are also alterations in the
renin–angiotensin system (RAS), probably
downstream to activation of the HPA axis. It is
not known if renin secretion from the
juxtaglomerular apparatus decreases in
parallel with the decrease in glomerular
number; however, the alterations in RAS
function and compensatory responses for
reduced kidney function probably account for
the predisposition to adult hypertension. Poor
fetal nutrition and other stress factors act
through similar mechanisms.
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Strategy for conditional knockout of a target gene in fetal or placental
tissues. The left-hand panel shows the process for developing a
targeted mouse homozygous for a floxed gene. The wild-type gene of
interest is selected and a targeting construct made, in which an
essential exon (Ex2) is flanked with loxP sites by gene replacement. A
neomycin-resistance cassette (Neo) equipped with a third loxP site is
cointroduced. The construct is then inserted into embryonic stem cells
by electroporation. Stem cells with homologous recombination are
selected and grown. These cells are transfected with a weak Cre
recombinase, with three possible results: total excision of exon 2 and
the Neo cassette; excision of exon 2; and excision of the Neo cassette.
The latter cells (i.e. with floxed exon 2) are selected and aggregated
with a blastocyst, which is transferred to the uterus of a
pseudopregnant mouse. Finally, a breeding program to establish germ-
line transmission yields a targeted line homozygous for the floxed gene.
The right-hand panel shows the production of a transgenic mouse
expressing Cre recombinase under the control of a promoter. The Cre
recombinase gene is linked to a promoter – for example, α-fetoprotein
promoter for fetal liver, the tie-1 promoter for fetal vessel endothelium
or the 4311 promoter for spongiotrophoblast. Following microinjection
of the construct into an oocyte, the 2–4 cell embryo is transferred to
the uterus of a pseudopregnant mouse. A breeding and screening
program yields a transgenic line expressing Cre recombinase under
the chosen promoter. Crossing the floxed targeted mouse with the
transgenic mouse expressing Cre recombinase with the desired
promoter results in the tissue-specific deletion of exon 2.
tie-1-Cre transgenic strain — where the enzyme is expressed
in endothelial cells of the embryo, yolk sac and placenta from
E10 until term — will allow direct deletion of floxed genes
involved in vasculogenesis and angiogenesis [49]. Transgenic
mice with embryonic-cell or placental-cell specific Cre
recombinases are currently under development (Figure 2).
Gene-dosage effects
The Cre-loxP system can also be used to explore gene-dosage
effects. A variable reduction in IGF-I levels has been
achieved by crossing mice with a loxP-flanked Igf1 locus
and mice expressing Cre recombinase under an adenovirus
promoter that is expressed early in embryonic development
[50]. In mice with the most severe recombination (Igf1
gene dosage 10–40% of normal), birth weight was reduced
by 31%, as in the classical Igf1 knockout experiment [31].
However, mice with Cre-induced partial recombination
(gene dosage 50–90% of normal) had a birth weight
reduction of only 12% and a phenotype that allowed
postnatal survival [50].
In utero gene transfer
Developmental disorders that can be diagnosed early in
gestation may become treatable in utero by gene therapy.
Gene transfer to multiple organs and transgene expression
has been achieved after vector administration via the
peritoneal cavity to rhesus monkey fetuses [51]. Moreover,
treatment of fetal monkeys with an adenovirus expressing
the cystic fibrosis transmembrane conductance regulator
(Cftr) gene has been shown to result in accelerated lung
differentiation [52•]. Finally, as gene transfer to mice at
E15 results in prolonged transgene expression [53], this
technique could be exploited as an experimental tool in
future studies of fetal growth and development.
Update
A recent study advances our understanding of how 
trophoblast differentiation is directed in mouse placenta
[67•]. Expression of nodal (a member of the TGF-β family)
is restricted to the spongiotrophoblasts and may direct 
trophoblast cell fate towards development of the labyrinth.
Nodal–/– placentae have an excessive number of giant cells
with total loss of the spongiotrophoblast and labyrinth
layers. A hypomorphic nodal allele has now been generated
by insertion of loxP sites. In placentae heterozygous for the
null allele and the hypomorphic allele, all cell layers were
present. However, the giant-cell layer and the spongiotro-
phoblast layer were increased in thickness at the expense
of the labyrinth. Thus, Nodal expression by the spon-
giotrophoblasts may direct labyrinth development from
one side, while signals at the interface of chorion and 
allantois, such as Gcm1 [5•], direct it from the other. 
The critical role of VEGF in fetal and placental development
has been further highlighted by null mutation of the Lkb1
gene, which encodes a serine/threonine kinase [68]. Lkb–/–
mice exhibited multiple embryonic abnormalities, poor
yolk-sac vascularization and a complete absence of fetal
vessels in the placenta. Death ensued at E8.5–11. This
phenotype was associated with deregulation of VEGF in
the embryonic and extraembryonic compartments.
The programming effects of prenatal glucocorticoid exposure
may not depend on a reduction in fetal growth. In a
carefully controlled study, glucose homeostasis in lambs
was affected by betamethasone administration to either
mother or fetus during late gestation. Yet fetal growth
restriction and altered blood pressure control occurred only
when glucocorticoids had been given to the mother [69•].
These findings add further support to the view [41•] that
programming of arterial blood pressure and glucose 
tolerance are not the result of a common mechanism.
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